Trevena TRVN shares traded higher on Monday after the company announced the initiation of its TRV027 study in COVID-19 patients in collaboration with Imperial College London.
Trevena is an American biotechnology company. The portfolio pipeline is focused on medicines targeting pain management: TRV734: oral medicine for moderate to severe pain; TRV250: oral medicine for migraines; and TRV027: treatment for acute heart failure. Its leading product is oliceridine (TRV130), a protein-based chemical meant to manage moderate to severe acute pain.
After opening at $1.77, Trevena's shares were trading lower at $1.56 at the time of publication. The stock has a 52-week high of $3.68 and a 52-week low of 46 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
